explore -WSS

explore

author：hotspot 2025-10-03 00:38:49 - browse：662

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Wikipedia

WSS

Testing for cancer recurrence creates a new limbo for patients

WHO may add ‘noma' to its list of neglected tropical diseases

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Chimpanzees, like humans and whales, get menopause: Study

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

CDC recommends rationing of RSV shot due to shortages

knowledge

explore

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Apple is now the first public company to be valued at $3 trillion

Data integrity in scientific journals requires "effort" by publishers, institutions

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Sports medicine is finally prioritizing gender equality

Cytokinetics CEO stresses company can launch heart drug on its own

Supreme Court strikes down use of affirmative action

WHO may add ‘noma' to its list of neglected tropical diseases

leisure time

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Case highlights the risks of experimental stem cell therapy

Cassava reveals details — and problems — with Alzheimer's study

Why Sanofi got shellacked over its spinoff

Senate panel to vote on hospitals, PBMs, prisoner care

Anxious about a speech? A startup wants you to pop a minty cardiac drug

hotspot

Wikipedia

Wikipedia

entertainment